VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events
Item 8.01 Other Events.
On June 17, 2020, VBI Vaccines Inc. (the “Company”) issued a press release announcing that members of the Company’s management team will participate in various upcoming virtual investor conferences. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press Release dated June 17, 2020|
VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm Exhibit 99.1 VBI Vaccines to Present at Upcoming Investor Conferences CAMBRIDGE,…
To view the full exhibit click
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).